How does xanomeline affect the brain?: A novel approach targeting muscarinic receptors
•
4 min read
In September 2024, the FDA approved xanomeline-trospium (Cobenfy) for the treatment of schizophrenia, representing the first new class of antipsychotic medication to market in decades that does not primarily target dopamine receptors. Understanding **how does xanomeline affect the brain?** requires exploring its innovative mechanism centered on the brain's cholinergic system, a fundamental pathway for cognition and behavior.
